FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular to novel double agonists of GLP-1 and GLP-2 receptors, and can also be used in medicine. Disclosed are compounds of general formula (1):
(1), where Q, W, X, Y, Z, AA1, AA2, AA3, AA4, AA5, AA6, AA7, AA8, AA9, LysR, R1, R2 and n are defined in this document.
EFFECT: invention can be used in treating, preventing, relieving, controlling or reducing the risk of disorders associated with glucagon-like peptide (GLP) receptors.
24 cl, 3 dwg, 4 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ORAL GLP RECEPTOR AGONISTS | 2021 |
|
RU2836443C1 |
| 2-((4-(4-(BENZYLOXY)PYRIMIDIN-2-YL)PIPERAZIN-1-YL)METHYL)-1H-BENZO[d]IMIDAZOLE DERIVATIVES AS LOW-MOLECULAR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS | 2024 |
|
RU2838323C1 |
| OXYSTEROLS AND THEIR APPLICATION METHODS | 2017 |
|
RU2754130C2 |
| AZOLE AND THIAZOLE DERIVATIVES AND USE THEREOF | 2006 |
|
RU2436779C2 |
| DERIVATIVES OF HEXAHYDRODIAZEPINONE, PHARMACEUTICAL COMPOSITION CONTAINING THEREOF AND USING IN PREPARING MEDICINAL AGENT FOR TREATMENT OF NON-INSULIN DEPENDENT DIABETES MELLITUS | 2003 |
|
RU2301803C2 |
| COMPOUNDS AND METHODS FOR ENHANCED DEGRADATION OF TARGET PROTEINS AND OTHER POLYPEPTIDES BY AN E3 UBIQUITIN LIGASE | 2013 |
|
RU2666530C2 |
| COMPOUNDS AND METHODS FOR ENHANCING DEGRADATION OF TARGET PROTEINS AND OTHER POLYPEPTIDES, USING E3 UBIQUITIN LIGASE | 2013 |
|
RU2781452C2 |
| SUBSTITUTED 3-AZABICYCLO[3_1_0]HEXANES AS KETOHEXOKINASE INHIBITORS | 2016 |
|
RU2696269C1 |
| CYCLIC AZAINDOLE-3-CARBOXAMIDE, PRODUCTION AND USE THEREOF AS THERAPEUTIC PREPARATIONS | 2009 |
|
RU2487874C2 |
| AMYLOID-BINDING AGENTS | 2010 |
|
RU2517174C2 |
